Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bioverativ: More Than Just A Hemophilia Company

Executive Summary

The blood disease specialist, to be acquired by Sanofi, is best known for its two marketed hemophilia drugs, but Bioverativ spent 2017 working on business development and diversifying beyond hemophilia. Scrip talked to CEO John Cox about the pipeline just before the merger was announced.


Related Content

Biopharma Quarterly Dealmaking Statistics, Q1 2018
Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Bicycle Partners With Biogen Spinout Against Rare Blood Disorders
Bioverativ Fills Gap In Pipeline With $400m True North Buy
Bioverativ Hits The Street Ready To Expand In Blood Disorders


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts